Background: Profound disturbances in mineral metabolism are closely linked to
have direct pathological consequences for the heart. Alterations in plasma PTH levels are associated with cardiac dysfunction and detrimental cardiac remodelling. Several clinical studies have associated vitamin D deficiency with the prevalence of cardiovascular disease (CV) and its risk factors. Recent evidences support deleterious direct and nonphosphaturic effects of FGF-23 on the heart as hypertrophy development. In contrast, reduced systemic klotho levels are related to CV damage, at least when advanced age is present. In addition, we discuss how these mineral metabolism molecules can counteract each other in some situations, in the context of failed clinical trials on cardiac protection as is the case of vitamin D supplementation. Conclusions: Among all mineral components, an increase in systemic FGF-23 levels is considered to have the greatest CV impact and risk. However, it is quite possible that many intracellular mechanisms mediated by FGF-23, especially those related to cardiomyocyte function, remain to be discovered. mineral metabolism components, fibroblast growth factor (FGF)-23 and its co-receptor klotho, 3 are intimately involved in the control of systemic phosphate homoeostasis. Alterations in these components have been traditionally circumscribed to patients with renal disease; however, in the last decades, a large number of clinical and basic/experimental studies have provided evidence that abnormalities in these mineral components can also trigger important and even independent cardiotoxic effects. Accordingly, it is now known that changes to the levels of these systemic mineral components increase, directly and indirectly, cardiovascular (CV) risk in patients with chronic kidney disease (CKD). Beyond the nephropathological context, these changes are also independently associated with clinical cardiac disease and its complications, including left ventricular hypertrophy (LVH), 4 heart failure (HF) 5 and atrial fibrillation (AF), 6 among others.
For instance, a deficiency in vitamin D is considered a predictor of reduced survival in patients with HF. 7 Similarly, several recent prospective trials and meta-analyses have shown that supraphysiological circulating levels of the nonclassical component FGF-23 have high prognostic value for predicting CV mortality and all-cause mortality. 8, 9 Therefore, alterations in mineral metabolism components, both classical and nonclassical, should be globally considered as functionally comparable along the cardiorenal continuum, but also in specific cardiac diseases beyond the confines of nephrology. in the proximal renal tubule, which promotes the absorption of calcium and phosphorus in the gut. In addition to serum calcium, phosphorus and vitamin D also fine-tune the secretion of PTH through negative and positive feedback loops. Deficient or enhanced secretion of PTH can lead to alterations in this process, stimulating changes in calcium homoeostasis. PTH is known to play an important role in the regulation of bone, kidney and intestine metabolism, but also has effects on the heart. Accordingly, several CV diseases such as hypertension, calcific valve disease and HF are associated with PTH disorders. [10] [11] [12] Increased levels of PTH have been also associated with increased myocardial electrical vulnerability, triggering cardiac arrhythmias. 13 The sustained activation of parathyroid glands in patients with CKD induces parathyroid hyperplasia, and elevated PTH levels lead to hyperphosphatemia and hyperkalemia, thereby increasing directly and indirectly the CV risk of these patients. 14 Both primary (PHPT) and secondary (SHPT) hyperparathyroidism share common metabolic features that provoke the over-secretion of PTH, and can lead to hypercalcemia. Patients with PHPT have increased mortality rates that derive in many cases from CV complications such as HF, hypertension, stroke or LVH. 15, 16 Chronic hypercalcemia is also related to calcification of cardiac valves and vessels, impairing CV function in this patient group. 15, 16 Correspondingly, some studies have reported an improvement in cardiac hypertrophy development in PHPT patients who underwent parathyroidectomy. 17 SHPT is usually accompanying CKD and has also been associated with CV diseases such as pulmonary hypertension or HF.
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SHPT has recently emerged as a complication of HF, and some authors showed more severe disease in failing patients with elevated serum PTH levels compared to patients with normal PTH levels. 19 Despite the common use of parathyroidectomy in the last decade, the new calcimimetics has progressively declined this practice, especially in elderly patients, in which it has been described that cinacalcet significantly reduces the risk of death and the incidence of major CV events. 20 In hypoparathyroidism, the low levels of PTH resulting from congenital or acquired diseases also lead to mineral imbalances, and the associated hypocalcemia has been linked to cardiac arrhythmias, cell contractility impairment and dilated cardiomyopathy development.
At the cellular level, it has been reported that PTHdependent pathways participate in specific pathophysiological processes implicated in cardiomyocyte function, such as contraction, hypertrophy, proliferation and apoptosis. The direct relationship between cardiac complications and PTH levels is supported by the direct effects of PTH on the regulation of intracellular calcium dynamics in adult cardiomyocytes. For example, PTH induces an increase in the intracellular calcium concentration due to activation of Ltype calcium channels and secondary mobilization of calcium from the sarcoplasmic reticulum (SR) to the cardiomyocyte cytoplasm. 23 Moreover, the over-stimulation of PTH-dependent pathways through PTH-related protein (PTHrP) and PTH-1 receptor (PTH-1R) increases intracellular calcium and activates protein kinase C and the prohypertophic programme in cardiomyocytes. 24 The activation of this PTHrP-/PTH-1-dependent pathway was found to induce p42-MAP kinase activation and the re-expression of the fetal programme in cardiomyocytes, which is involved in the early stage of cardiac hypertrophy. 25 In addition, the high PTH plasma levels observed in uremic rats seem to be responsible, at least in part, for the cardiac hypertrophy and cardiac fibrosis observed in this experimental model. 26 Supporting these data, studies in neonatal rat ventricular myocytes have also shown that increased concentrations of PTH provoke cellular hypertrophy through MEK/ERK pathway activation. 27 Moreover, dramatic physiological effects are observed when cardiomyocytes are incubated with PTH, which results in an increase in cellular contractions/min and premature cell death. 28 By contrast, low concentrations of PTH have been shown to improve cell shortening by increasing calcium load in isolated rat cardiomyocytes. 29 These ostensibly contradictory experimental findings suggest that PTH can induce pleiotropic effects on cardiac function that are concentration and timing dependent. Overall, the experimental evidence supports the aforementioned clinical studies and strongly suggests that alterations in plasma PTH levels are associated with detrimental cardiac remodelling, hypertrophy and function.
| Vitamin D deficiency and its association with cardiac alterations
Vitamin D is a steroid hormone that can be produced endogenously or by dietary consumption. The principal source of vitamin D in the body is its synthesis in the skin by UVB irradiation in the epidermis to form pre-vitamin D3, which is immediately converted to cholecalciferol (vitamin D3). This precursor form of vitamin D is transformed in the liver to 25(OH)D3, which is the major circulating form of vitamin D that is usually measured by clinicians to determine vitamin D status. This form of vitamin D is biologically inactive and must be converted by 25-hydroxyvitamin D-1-a-hydroxylase to the biologically active form 1,25-(OH)2D3, which occurs in the kidneys and in other tissues. Circulating 1,25-(OH)2D3 crosses the cell membrane and cytoplasm and reaches the nucleus of the cell to bind to vitamin D receptors (VDRs), which in turn can bind to retinoid acid receptors, to collectively serve as nuclear ligand-activated transcription factors to modulate the expression of genes containing a vitamin D3 response element. 30 In addition to this classical genomic response, the available data support the view that 1,25-(OH)2D3 can induce "rapid responses" via plasma membrane-associated VDR, involving the modulation of ion channels 31 and membrane-based signalling pathways. 32 The 34 Using the same experimental model, Bae et al. 35 demonstrated that paricalcitol prevented the progression of pre-existing cardiac hypertrophy and also the development of HF. Moreover, using a murine model of surgically induced myocardial infarction (MI), the same group showed that paricalcitol attenuated the development of HF by reducing infarct size as well as markers of inflammation, fibrosis, apoptosis and activation of reninangiotensin-aldosterone system. 36 Vitamin D receptors have been identified in the transverse tubules of adult ventricular cardiomyocytes. Many of the proteins involved in excitation-contraction coupling are concentrated in this region, including L-type calcium channels, which play a critical role in regulating calcium-dependent signalling and contractility function in cardiomyocytes. 37 Supporting the involvement of VDR signalling in this region, 1,25-(OH)2D3 treatment of mouse ventricular myocytes was shown to result in a rapid, nongenomic VDR-dependent increase of L-type calcium current via PKA signalling, enhancing calcium extrusion from the SR and also contraction. 31 The role of VDR-mediated signalling in the hypertrophic response has been further elucidated by the use of knockout mice. Mice with systemic deletion of VDR are hypertensive, and their heart weight/body weight ratios are significantly elevated, suggesting the development of NAVARRO-GARC IA ET AL. | 3 of 10 cardiac hypertrophy. 38 Moreover, they present SHPTH, which complicates the interpretation of parameters in relation to vitamin D-VDR signalling. To better understand the role of VDR in the heart, Chen et al. 39 generated a mouse model with a selective deletion of the VDR gene in cardiomyocytes, which was also found to be associated with cardiac hypertrophy. The results of this study showed that vitamin D-VDR signalling possesses direct antihypertrophic activity on the heart that was, at least in part, associated with the suppression of the prohypertrophic calcineurin/ NFAT/MCIP1 pathway. At the clinical level, deficiency in vitamin D has been historically associated with rickets in children and osteomalacia and osteoporosis in adults. Unfortunately, deficiency of vitamin D remains highly prevalent worldwide, impacting between 30% and 50% of the general population. 40 Numerous observational and prospective studies have associated vitamin D deficiency with the prevalence of many chronic comorbidities, including CV disease and its risk factors. Moreover, clinical studies show a clear association between vitamin D deficiency and the prevalence of CV disease (coronary heart disease, HF and stroke), as well as total mortality. Despite the abundance of relevant clinical data, it remains unclear whether FGF-23 is the cause or consequence of CV diseases. Interestingly, several recent studies have shown that stressed cardiomyocytes can induce its own synthesis of FGF-23, [60] [61] [62] presenting the new paradigm that the heart per se can respond to local damage by synthesizing FGF-23, and supporting the notion that it can also be a possible cardiac pathological consequence.
In the last few years, many efforts have been made to identify the pathophysiological mechanisms involved in the cardiotoxic effects of FGF-23. It appears that the cardiac effects of FGF-23 are linked mainly to FGF-receptor 4 (FGFR4), which is the FGFR isoform with more affinity for FGF-23 in the heart. 63, 64 In this sense, the seminal work of Faul and colleagues 4 showed for the first time that pathological levels of FGF-23 (10, 25 and 100 ng/mL) induced cardiomyocyte hypertrophy via activation of the PLCccalcineurin-NFAT-dependent pathway, but was independent of klotho signalling. Consistent with these in vitro effects, the chronic administration of a pan-FGF-receptor (FGFR) blocker was found to attenuate LVH in 5/6 nephrectomized rats (a classical experimental CKD model) presenting high levels of serum FGF-23. Thus, at least in this model, FGF-23 is active in the development of nephrotic cardiomyopathy. 4 Similar findings of cardiac hypertrophy were reported in the klotho-deficient mouse, 65 which was first developed as a premature ageing model 62 and is characterized by hyperphosphatemia and high circulating levels of FGF-23. Studies using experimental models of direct cardiac damage have been very useful to test whether FGF-23 is a pathophysiological factor causally linked to progression of cardiac dysfunction. Thus, transverse aortic constriction (TAC) in wild-type mice, an experimental model of pressure overloadinduced cardiac hypertrophy, induced a strong increase in serum FGF-23 levels that was accompanied by upregulation of cardiac but not bone FGF-23 expression, demonstrating that the heart per se is able to express FGF-23 under pressure overload conditions. 66 Overall, these clinical and experimental data demonstrate an intimate relationship between cardiac damage and FGF-23 and support the concept that FGF-23 could be a stronger cardiac toxin than it is a renal toxin. The phosphaturic action of FGF-23 protects against systemic phosphate overload, but at the same time triggers inherent deleterious cardiac damage. However, the specific cardiac mechanisms mediated by FGF-23, in particular those involved in modulating cardiomyocyte contractile properties leading to cardiac dysfunction, remain to be discovered.
| Klotho and heart: the potential cardioprotective role of soluble klotho
Klotho is predominantly synthesized in the kidney, but it is also expressed in choroid plexus and parathyroid glands. 65 It is a transmembrane protein that forms complexes with FGF receptors (FGFRs), thereby increasing the affinity of FGFRs specifically to FGF-23. 67, 68 There are two known isoforms of membrane klotho: a-klotho, present in the kidney, and b-klotho, which is found in various peripheral metabolic tissues. Membrane klotho can be shed by secretases to release a soluble form (sklotho) into the blood, where it is predominant over a-klotho in humans. 69, 70 As mentioned earlier, klotho was first described in a mouse premature ageing model, 62 and for this reason, it is commonly known as an ageing suppressor gene. Whereas klotho-deficient mice exhibit premature ageing and premature death, 65 mice overexpressing klotho have a longer lifespan than do wild-type mice. 71 At the cardiac level, Hui and colleagues 72 recently showed that a significant decrease in sklotho levels in ageing mice was associated with cardiac dysfunction. Moreover, when these ageing mice were treated with recombinant klotho, they showed an improvement in cardiac function. Mechanistically, the cardioprotective actions of recombinant klotho were found to be dependent on anti-inflammatory mechanisms, including the activation of myocardial Hsp70, and the inhibition of NF-jB activation. 72 Several authors have postulated that alterations in klotho expression are related to the development of cardiac hypertrophy, but these observations are provocative. Thus, some authors have described the finding of LVH in unstressed klotho-deficient mice 4,51 under basal conditions. By contrast, another study using the same model reported no basal cardiac abnormalities, 73 whereas in the presence of b-adrenergic overload through isoproterenol administration knockout mice developed greater hypertrophy than did wild-type mice. 73 The cardioprotective action of klotho was found to be mediated by the downregulation of TRPC6 cation channels in the heart. 73 The cardioprotective role of klotho in hypertrophy development is also supported by in vitro experiments. Neonatal cardiomyocytes treated with angiotensin II to induce cellular hypertrophy showed a smaller cell area and decreased b-myosin heavy chain (bMHC) expression in the presence of klotho, supporting the idea that it protects against cardiac damage related to hypertrophy. 74 However, no differences in hypertrophy were observed between klotho-deficient mouse and wildtype mice in a TAC model of cardiac hypertrophy. 66 Although the main source of klotho is the kidney, hearts subjected to stress have been found to induce klotho expression. Accordingly, it has been described that klothodeficient mice cannot increase their heart rate to compensate for stress-conditioned stimuli, which subsequently provokes a high rate of sudden death due to sinoatrial (SA) node dysfunction. 75 This study supports the idea that klotho is key for the maintenance of the correct function of the SA node and adequate cardiac rhythm. In addition, a recent study has shown that klotho can be expressed in human hearts and also that its expression is reduced in patients with higher CV risk. 61 While no clinical study has yet described an association between reduced sklotho levels and CV mortality in the general population, 76 a negative correlation between skotho and age has been found in different cohorts, 77, 78 suggesting that sklotho is an independent predictor of all-cause mortality in the elderly population. 79 Moreover, elevated levels of circulating sklotho in elderly individuals are believed to be associated with a lower risk of developing CV disease, even after adjusting for traditional CV risk factors. 77 By contrast, among elderly patients with preserved ejection fraction, lower levels of sklotho are observed in patients with LV diastolic function than in those with no diastolic function. Due to its anti-ageing effects, it seems to be clear that a deficit in klotho is associated with CV damage as long as the component of advanced age is present. Nevertheless, more studies are needed to better understand the role of klotho in the heart under stress conditions for it to be considered as a new potential therapeutic option. Figure 1 shows the interactions between PTH, vitamin D, FGF-23 and klotho through negative or positive feedback mechanisms to control phosphate homoeostasis, and the pathological or the protective role of each one on the heart.
| COUNTERACTING MINERAL METABOLISM COMPONENTS AND HEART
Parathyroid hormone and vitamin D are considered classical and major regulators of mineral metabolism. PTH is the main stimulator of vitamin D synthesis in the renal system, which negatively controls PTH secretion as a feedback mechanism. These established mineral metabolism components also control the synthesis of the recently discovered nonclassical mineral metabolism components such as FGF-23, 80 which at the same time blocks 1 a-hydroxylase on the proximal renal tubules, inducing a decrease in the levels of 1,25-(OH)2D3 and resulting in parathyroid gland dysfunction and increased secretion of PTH. The balance between all these components regulates phosphate homoeostasis under physiological conditions (Figure 1 ). Although it is clear that disorders in these classical and nonclassical mineral metabolism components are directly and indirectly associated with cardiac alterations, the mineral component demonstrating its association with all-cause mortality, especially CV mortality. 8 An elevation in FGF-23 systemic levels is associated with AF and LVH. 4, 6 There is no clear association between increased FGF-23 systemic levels and incidence of MI, and whether FGF- Other options such as directly blocking FGF-23 actions are attracting increasing attention as potential therapies. However, this must be approached with caution because inhibiting the phosphaturic action of FGF-23 in a hyperphosphatemic environment could worsen complications, especially uremic cardiomyopathy, since the main role of FGF-23 is to reduce the toxicity of systemic phosphate overload. In fact, FGF-23 knockout mice present elevated 1,25-(OH)2D3 and calcium serum levels together with robust hyperphosphatemia and premature death. 90 Feeding these mice, a vitamin D-deficient diet normalizes calcium and 1,25-(OH)2D3 levels and improves survival despite the background of persistent hyperphosphatemia. 90 Therefore, an excessive activity of vitamin D can be self-defeating and can have adverse effects in systemic conditions of hyperphosphatemia and with the absence of FGF-23.
| CONCLUSIONS AND FUTURE

DIRECTIONS
The main conclusions from this article are presented in Table 1 . For many years, hyperphosphatemia has been considered as one of the major risks that accelerates clinical complications such as CV events, especially in CKD patients. However, assuming the clinical importance of controlling phosphatemia, it is crucial not to forget that alterations in mineral hormones involved in phosphate homoeostasis can exert direct and indirect deleterious effects on the heart. New therapeutic strategies directed not only to lower circulating phosphate levels, but also to preserve the homoeostasis between all mineral metabolism components and to avoid the deleterious cardiac action of classical and nonclassical mineral hormones, are clearly needed to improve the prognosis and reduce the CV risk of patients with alterations in mineral metabolism. In this sense, in a post hoc analysis of the Evaluation of Cinacalcet HCI Therapy to Lower Cardiovascular Events (EVOLVE) trial, the calcimimetic cinacalcet was shown to decrease FGF-23 levels, which were associated with lower rates of CV events. 91 In this study, the major benefit of FGF-23 lowering by cinacalcet was dependent on the reduction of the other well-known modifiers of FGF-23 levels, PTH, calcium and phosphate. sklotho might also represent a potential valuable therapeutic option. The latest evidence, particularly from animal studies, supports the idea that klotho supplementation, in addition to its renal protective action, can also function as a cardioprotective factor. 72 Therefore, administration of sklotho may be a valuable therapeutic strategy, at least to preserve the heart from the deleterious effects exerted by a pathological elevation in FGF-23 systemic levels, especially in those 5. There are many gaps in our knowledge related to the physiological role klotho in the heart that have to be filled before establishing soluble klotho as a cardioprotective therapeutic option
